{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:14:57Z","timestamp":1783646097027,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2026.03.050","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:32:18Z","timestamp":1774283538000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of early treatment of psoriasis on disease recurrence\u2014Results from the STEPIn study"],"prefix":"10.1016","volume":"95","author":[{"given":"Lars","family":"Iversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Narbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Czajkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rivera-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj A.","family":"Gianchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kolbinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Jagiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3440","authenticated-orcid":false,"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2026.03.050_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jvc2.63","article-title":"Early intervention and disease memory in psoriasis: a literature review","volume":"1","author":"Ben Abdallah","year":"2022","journal-title":"JEADV Clin Pract"},{"issue":"3","key":"10.1016\/j.jaad.2026.03.050_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2133.2012.10991.x","article-title":"Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France","volume":"167","author":"Maza","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.03.050_bib6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","article-title":"The prevalent comorbidome at the onset of psoriasis diagnosis","volume":"13","author":"Buja","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2026.03.050_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.jaad.2026.03.050_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112849","article-title":"Could targeted pharmacotherapies exert a \"disease modification effect\" in patients with chronic plaque psoriasis?","volume":"23","author":"Bellinato","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jaad.2026.03.050_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/ced\/llad329","article-title":"Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies","volume":"49","author":"Lebwohl","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.03.050_bib10","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.jaad.2026.03.050_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.03.050_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/09546634.2014.880396","article-title":"Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper","volume":"26","author":"Girolomoni","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2026.03.050_bib13","article-title":"Early intervention in psoriasis: where do we go from here?","volume":"9","author":"Felix","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2026.03.050_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107925","article-title":"Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety","volume":"229","author":"Kolbinger","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","article-title":"Secukinumab: a review in moderate to severe plaque psoriasis","volume":"16","author":"Garnock-Jones","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","article-title":"Secukinumab: a review in psoriatic arthritis","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2026.03.050_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-016-0598-8","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2026.03.050_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10378","key":"10.1016\/j.jaad.2026.03.050_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2026.03.050_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study","volume":"37","author":"Iversen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2026.03.050_bib21","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.14979","article-title":"Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study","volume":"32","author":"Iversen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2026.03.050_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.03.050_bib24","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2026.03.050_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.03.050_bib26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jaad.2026.03.050_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2023.03.838","article-title":"(Poster 828). Early intervention with secukinumab may affect the establishment of tissue memory in psoriasis: results from a DNA methylation analysis","volume":"143","author":"Conrad","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.03.050_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: from pathogenesis to targeted therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2026.03.050_bib29","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jaad.2026.03.050_bib30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4049\/jimmunol.2400020","article-title":"Skin-resident T cells contribute to the dynamic disease manifestations of psoriasis","volume":"213","author":"Sortebech","year":"2024","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2026.03.050_bib31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/jid.2011.53","article-title":"Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways","volume":"131","author":"R\u00e1cz","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.03.050_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archderm.142.7.836","article-title":"Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy","volume":"142","author":"Yones","year":"2006","journal-title":"Arch Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2026.03.050_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04519.x","article-title":"Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226004597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226004597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:01:35Z","timestamp":1783645295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226004597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0190962226004597"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.050","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of early treatment of psoriasis on disease recurrence\u2014Results from the STEPIn study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}